You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
NEB plans to expand its product lines into new areas of research including genome editing, the companies said.
Last week's SynBioBeta conference was indicative of the high degree of interest in the synthetic bio space from omics research tool vendors.
This week's news includes Adaptive Biotechnologies, Thermo Fisher Scientific, TATAA Biocenter, and New England Biolabs.
The new partnership will support the analysis of glycans in 30,000 human samples by the end of 2021.
New England Biolabs is using Avacta's affimers with a development-stage research and diagnostic assay that could launch as early as next year.
The partnership will allow customers using NEBNext Direct target enrichment products to analyze data with the Bluebee platform.
The two companies will work to characterize new Cas nucleases, and NEB will then manufacture and commercially distribute the nucleases globally.
The services will couple NEB's reagents and expertise in enzyme development and manufacturing with TTP's Desktop Biology product development and engineering know-how.
Researchers outlined the "nicking enzyme-assisted sequencing" (NicE-seq) protocol and presented results from proof-of-principal open chromatin profiling experiments.
Researchers have developed a robotic lab assistant, the Verge reports.
CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.
The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.
In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.